vendredi 12 juin 2020

Onco Actu du 12 juin 2020

DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES
NIH scientists develop blood test to help improve liver cancer screening [NIH] 
The team checked for the footprints of more than 1,000 different viruses in blood samples from around 900 people, including 150 who had HCC. They identified a specific viral exposure signature that could accurately distinguish people with HCC from people with chronic liver disease and healthy volunteers. This signature contained footprints from 61 different viruses.

TRAITEMENTS - PRÉ-CLINIQUE
Computer algorithms find tumors’ molecular weak spots [Science] 
In 2015, Califano co-founded a company called DarwinHealth that uses his algorithms to guide doctors by identifying the key transcription factors in a patient’s tumor and suggesting drugs to target them.
 

IMMUNOTHÉRAPIES - BIOTECH
Fueled with a fresh cash injection, Cullinan expands its pipeline with a bid to develop a new combination drug for the checkpoint class [EndPoints] 
As CSO and co-founder Baeuerle explains it, the MICA ligand plays a key role in allowing NK and other killer T cells to mount an attack on cancer cells. And patients with high levels of MICA have a particularly poor prognosis.

Juno, WuXi JV in China score $100M in fresh funding as it sets stage for first CAR-T approval [EndPoints] 
The Shanghai-based company, christened JW Therapeutics (an initial each from its root companies), was created to marry Juno’s CAR-T development experience and WuXi’s AppTec’s muscular manufacturing capacity.

IMMUNOTHÉRAPIES - AMM
The Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, …
Putting ‘Super’ in Natural Killer Cells [UCSD] 
Deleting an inhibitory gene in natural killer cells derived from induced pluripotent stem cells is found to boost their anti-tumor activity and persistence; researchers now seek to develop a clinical therapy.

TRAITEMENTS - AMM
With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era [NCI] 
The approvals are for the drugs olaparib (Lynparza) and rucaparib (Rubraca). They cover the use of the drugs in men whose prostate cancer has spread, or metastasized, and whose disease has stopped responding to standard hormone treatments, often called castration-resistant disease. 

FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf) [Pfizer] 
The FDA approval was based on the review of a comprehensive data package and totality of evidence demonstrating a high degree of similarity of NYVEPRIA to its reference product.

EHA
Detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia.

LUTTE CONTRE LES CANCERS - PUBLICATIONS
Institute ends negotiations for a new journals contract in the absence of a proposal aligning with the MIT Framework for Publisher Contracts.

LUTTE CONTRE LES CANCERS - IMPLANTS MAMMAIRES
Only French victims of faulty breast implant may claim damages, EU court says [Reuters] 
“The regulation favours international exchanges of products, which is a good thing, but consumer protection stops at the border,” said Olivier Aumaitre, a lawyer for the association.

LUTTE CONTRE LES CANCERS - ASSOCIATIONS
American Cancer Society Reductions in Wake of Fundraising Drop from Coronavirus Pandemic [ACS] 
ACS is reducing its overall budget by approximately 30 percent, with cuts to both non-personnel and personnel expenses. Unfortunately, this included eliminating approximately 1,000 staff positions nationwide.